The GSK3β inhibitor AR-A014418 effectively counteracted the effects of GAD1 knockdown, suppressing the enhanced proliferation, cell cycle progression, and invasion of glioblastoma cells, while also reducing the expression of p-GSK3β, β-catenin, Cyclin D1, and MMP9. Here, GAD1 is linked to glioblastoma.